Raymond James Reinstates Outperform on Xenon Pharmaceuticals, Announces $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and set a price target of $50.
October 10, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Xenon Pharmaceuticals with a $50 price target, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating and a $50 price target by Raymond James suggests a positive outlook for Xenon Pharmaceuticals, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100